IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/2/2025 | $26.00 | Buy | H.C. Wainwright |
| 1/8/2025 | $25.00 | Overweight | Cantor Fitzgerald |
| 10/7/2024 | $20.00 | Buy | Guggenheim |
| 9/24/2024 | $17.00 | Mkt Outperform | JMP Securities |
| 9/24/2024 | $18.00 → $25.00 | Buy | Maxim Group |
| 4/2/2024 | $12.00 → $18.00 | Buy | Maxim Group |
| 3/12/2024 | Outperform | William Blair | |
| 3/17/2023 | $12.00 | Buy | Maxim Group |
Fastest customizable press release news feed in the world
CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 53,000 shares of the Company's common stock (the "Inducement Awards") to three new employees pursuant to the Company's 2023 Employment Inducement Award Plan (as amended and/or restated, the "Inducement Award Plan"). Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter
CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alicia Secor to the Company's Board of Directors (Board). The Company also announced the retirement of director Wendy Dixon, PhD, effective today. "We are pleased to welcome Alicia to our Board at this important juncture, as her expertise will support our continued execution of strategy and our commitment to delivering durable, sustained value for shareholders," said Tamara A. Favorito, Zevra's Chair of the Board. "We sincerely appreciate Wendy's
CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that its Chief Financial Officer and Treasurer, R. LaDuane Clifton, will be stepping down from his position with the Company, effective December 31, 2025, in order to pursue other professional opportunities. "Since joining the Company in 2015, LaDuane has provided steady leadership and invaluable guidance, leaving a lasting impact on the Company," said Neil F. McFarlane, Zevra's Chief Executive Officer and President. "He has played a pivotal role in our journey as w
2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the three and nine months ended September 30, 2025. "Zevra is well-positioned for continued growth, driven by the strong performance of MIPLYFFA and the meaningful impact we are delivering to patients with Niemann-Pick disease type C," said Neil F.
CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will participate in a fireside discussion at Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston, MA on Wednesday, November 12, 2025, at 11:30 a.m. ET. Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra's website at investor
CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the third quarter 2025 on Wednesday, November 5, 2025, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra's website at investors.zevra.com. To join via telephone, please use the following dial-in information: (800) 579-2543 (
CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 38,000 shares of the Company's common stock (the "Inducement Awards") to two new employees pursuant to the Company's 2023 Employment Inducement Award Plan (as amended and/or restated, the "Inducement Award Plan"). Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter (s
MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients OLPRUVA offers the established efficacy and safety of sodium phenylbutyrate in a novel and convenient formulation for the treatment of certain urea cycle disorders CELEBRATION, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an upcoming oral presentation at the International Niemann-Pick Disease All
New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award received for poster highlighting MIPLYFFA's differentiated mechanism of action targets underlying pathology of NPC CELEBRATION, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the presentation of several posters highlighting new positive data on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) for the treatment of Niemann-Pick disease typ
CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four posters on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM), taking place September 2-6, 2025, in Kyoto, Japan. MIPLYFFA is approved in the U.S. for the treatment of Niemann-Pick disease type C (NPC). A poster (# BP-19) detailing that MIPLYFFA's mechanism of action uniquely targets the underlying pathophysiology of NPC was selected for a Best Poster award. Additionally, positive, ne
8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
10-Q - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
10-Q - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
DEFA14A - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
10-Q - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $26.00
Cantor Fitzgerald resumed coverage of Zevra Therapeutics with a rating of Overweight and set a new price target of $25.00
Guggenheim initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $20.00
JMP Securities initiated coverage of Zevra Therapeutics with a rating of Mkt Outperform and set a new price target of $17.00
Maxim Group reiterated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $25.00 from $18.00 previously
Maxim Group reiterated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $18.00 from $12.00 previously
William Blair initiated coverage of Zevra Therapeutics with a rating of Outperform
Maxim Group initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $12.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
3 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)